214 related articles for article (PubMed ID: 8560759)
1. N-linked glycans in the CD4-binding domain of human immunodeficiency virus type 1 envelope glycoprotein gp160 are essential for the in vivo priming of T cells recognizing an epitope located in their vicinity.
Sjölander S; Bolmstedt A; Akerblom L; Horal P; Olofsson S; Morein B; Sjölander A
Virology; 1996 Jan; 215(2):124-33. PubMed ID: 8560759
[TBL] [Abstract][Full Text] [Related]
2. An endogenously synthesized decamer peptide efficiently primes cytotoxic T cells specific for the HIV-1 envelope glycoprotein.
Bergmann C; Stohlmann SA; McMillan M
Eur J Immunol; 1993 Nov; 23(11):2777-81. PubMed ID: 7693478
[TBL] [Abstract][Full Text] [Related]
3. Preferential V beta usage by cytotoxic T cells cross-reactive between two epitopes of HIV-1 gp160 and degenerate in class I MHC restriction.
Shirai M; Vacchio MS; Hodes RJ; Berzofsky JA
J Immunol; 1993 Aug; 151(4):2283-95. PubMed ID: 7688397
[TBL] [Abstract][Full Text] [Related]
4. Broad recognition of cytotoxic T cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules.
Shirai M; Pendleton CD; Berzofsky JA
J Immunol; 1992 Mar; 148(6):1657-67. PubMed ID: 1371784
[TBL] [Abstract][Full Text] [Related]
5. Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant. Immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein.
Martinon F; Gras-Masse H; Boutillon C; Chirat F; Deprez B; Guillet JG; Gomard E; Tartar A; Levy JP
J Immunol; 1992 Nov; 149(10):3416-22. PubMed ID: 1385524
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic T cell repertoire selection. A single amino acid determines alternative class I restriction.
Bergmann CC; Tong L; Cua RV; Sensintaffar JL; Stohlman SA
J Immunol; 1994 Jun; 152(12):5603-12. PubMed ID: 7515908
[TBL] [Abstract][Full Text] [Related]
8. An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes.
Stanhope PE; Liu AY; Pavlat W; Pitha PM; Clements ML; Siliciano RF
J Immunol; 1993 May; 150(10):4672-86. PubMed ID: 8097759
[TBL] [Abstract][Full Text] [Related]
9. Biological properties of recombinant HIV envelope synthesized in CHO glycosylation-mutant cell lines.
Fenouillet E; Miquelis R; Drillien R
Virology; 1996 Apr; 218(1):224-31. PubMed ID: 8615025
[TBL] [Abstract][Full Text] [Related]
10. CD4+ class I-restricted T cells specific for HIV gp160 315-329.
Moore RL; Fox BS
Cell Immunol; 1994 Mar; 154(1):43-53. PubMed ID: 7907008
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of CD4+ T cell activation and adhesion by peptides derived from the gp160.
Corado J; Mazerolles F; Le Deist F; Barbat C; Kaczorek M; Fischer A
J Immunol; 1991 Jul; 147(2):475-82. PubMed ID: 1677023
[TBL] [Abstract][Full Text] [Related]
12. Effect of partial and complete variable loop deletions of the human immunodeficiency virus type 1 envelope glycoprotein on the breadth of gp160-specific immune responses.
Gzyl J; Bolesta E; Wierzbicki A; Kmieciak D; Naito T; Honda M; Komuro K; Kaneko Y; Kozbor D
Virology; 2004 Jan; 318(2):493-506. PubMed ID: 14972518
[TBL] [Abstract][Full Text] [Related]
13. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research.
Redfield RR; Birx DL; Ketter N; Tramont E; Polonis V; Davis C; Brundage JF; Smith G; Johnson S; Fowler A
N Engl J Med; 1991 Jun; 324(24):1677-84. PubMed ID: 1674589
[TBL] [Abstract][Full Text] [Related]
14. The importance of dominant negative effects of amino acid side chain substitution in peptide-MHC molecule interactions and T cell recognition.
Boehncke WH; Takeshita T; Pendleton CD; Houghten RA; Sadegh-Nasseri S; Racioppi L; Berzofsky JA; Germain RN
J Immunol; 1993 Jan; 150(2):331-41. PubMed ID: 8093457
[TBL] [Abstract][Full Text] [Related]
15. Priming with T helper cell epitope peptides enhances the antibody response to the envelope glycoprotein of HIV-1 in primates.
Hosmalin A; Nara PL; Zweig M; Lerche NW; Cease KB; Gard EA; Markham PD; Putney SD; Daniel MD; Desrosiers RC
J Immunol; 1991 Mar; 146(5):1667-73. PubMed ID: 1704401
[TBL] [Abstract][Full Text] [Related]
16. Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response.
Bolmstedt A; Sjölander S; Hansen JE; Akerblom L; Hemming A; Hu SL; Morein B; Olofsson S
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):213-20. PubMed ID: 8673525
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic T lymphocytes from HIV-1 seropositive individuals recognize immunodominant epitopes in Gp160 and reverse transcriptase.
Lieberman J; Fabry JA; Kuo MC; Earl P; Moss B; Skolnik PR
J Immunol; 1992 May; 148(9):2738-47. PubMed ID: 1374097
[TBL] [Abstract][Full Text] [Related]
18. Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types.
Berzofsky JA; Pendleton CD; Clerici M; Ahlers J; Lucey DR; Putney SD; Shearer GM
J Clin Invest; 1991 Sep; 88(3):876-84. PubMed ID: 1715888
[TBL] [Abstract][Full Text] [Related]
19. Mapping of the human immunodeficiency virus type 2 envelope glycoprotein CD4 binding region and fusion domain with truncated proteins expressed by recombinant vaccinia viruses.
Otteken A; Voss G; Hunsmann G
Virology; 1993 May; 194(1):37-43. PubMed ID: 8480426
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 soluble antigens induced CD8+ cytotoxic T-cell responses in an immunized individual.
Achour A; Moukrim Z; Picard O; Bizzini B; Burny A; Zagury D
Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):395-400. PubMed ID: 7580833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
